Viracta Therapeutics, Inc.
VIRX · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | $1 |
| % Margin | – | – | – | 83.3% |
| R&D Expenses | $7 | $7 | $10 | $9 |
| G&A Expenses | $3 | $3 | $4 | $4 |
| SG&A Expenses | $3 | $3 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $10 | $10 | $14 | $13 |
| Operating Income | -$10 | -$10 | -$14 | -$14 |
| % Margin | – | – | – | -1,837.4% |
| Other Income/Exp. Net | -$0 | -$0 | $5 | -$0 |
| Pre-Tax Income | -$11 | -$10 | -$9 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$10 | -$9 | -$14 |
| % Margin | – | – | – | -1,865.2% |
| EPS | -0.27 | -0.25 | -0.23 | -0.35 |
| % Growth | -8% | -8.7% | 34.3% | – |
| EPS Diluted | -0.27 | -0.25 | -0.23 | -0.35 |
| Weighted Avg Shares Out | 40 | 39 | 39 | 39 |
| Weighted Avg Shares Out Dil | 40 | 39 | 39 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $1 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | -$9 | -$8 | -$13 |
| % Margin | – | – | – | -1,719.9% |